IPO - ACHIEVE LIFE SCIENCES, INC.

Form Type: 424B5

Filing Date: 2025-06-27

Corporate Action: Ipo

Type: New

Accession Number: 000095017025090991

Filing Summary: Achieve Life Sciences, Inc. is offering 15,000,000 shares of common stock along with accompanying common warrants as part of a public offering. Each common warrant is priced at $3.00 and will expire five years post-issuance. The shares will be sold together with the warrants but issued separately. The net proceeds from the offering are expected to be approximately $41.3 million, which will be utilized for the advancement of the cytisinicline product for nicotine dependence and for general corporate purposes. The company also recently announced the submission of a New Drug Application (NDA) for cytisinicline to the FDA for smoking cessation treatment. Additionally, the company has formed a strategic partnership with Omnicom Group Inc. to assist in its U.S. commercial launch of cytisinicline pending NDA approval.

Form Type: 8-K

Filing Date: 2025-06-27

Corporate Action: Ipo

Type: New

Accession Number: 000095017025091055

Filing Summary: On June 26, 2025, Achieve Life Sciences, Inc. entered into an underwriting agreement with Citizens JMP Securities, LLC and Raymond James & Associates, Inc. for an offering of 15,000,000 shares of common stock and accompanying warrants at a public offering price of $3.00 per share. The underwriters were granted a 30-day option to purchase an additional 2,250,000 shares and/or warrants. The offering is being conducted under the shelf registration statement filed with the SEC on June 28, 2024. Achieve estimates net proceeds of approximately $41.3 million from the offering, with expected closure on June 30, 2025, subject to customary conditions. A press release was also issued on June 26, 2025, announcing the commencement and pricing of the offering.